Literature DB >> 25742458

Anemia: progress in molecular mechanisms and therapies.

Vijay G Sankaran1, Mitchell J Weiss2.   

Abstract

Anemia is a major source of morbidity and mortality worldwide. Here we review recent insights into how red blood cells (RBCs) are produced, the pathogenic mechanisms underlying various forms of anemia, and novel therapies derived from these findings. It is likely that these new insights, mainly arising from basic scientific studies, will contribute immensely to both the understanding of frequently debilitating forms of anemia and the ability to treat affected patients. Major worldwide diseases that are likely to benefit from new advances include the hemoglobinopathies (β-thalassemia and sickle cell disease); rare genetic disorders of RBC production; and anemias associated with chronic kidney disease, inflammation, and cancer. Promising new approaches to treatment include drugs that target recently defined pathways in RBC production, iron metabolism, and fetal globin-family gene expression, as well as gene therapies that use improved viral vectors and newly developed genome editing technologies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25742458      PMCID: PMC4452951          DOI: 10.1038/nm.3814

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  117 in total

Review 1.  Hematologic manifestations of systemic disease (including iron deficiency, anemia of inflammation and DIC).

Authors:  Char M Witmer
Journal:  Pediatr Clin North Am       Date:  2013-10-04       Impact factor: 3.278

2.  The switch from fetal to adult hemoglobin.

Authors:  Vijay G Sankaran; Stuart H Orkin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

3.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Authors:  Emilio Ramos; Piotr Ruchala; Julia B Goodnough; Léon Kautz; Gloria C Preza; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

4.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

5.  Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development.

Authors:  C Q Wang; K B Udupa; D A Lipschitz
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

6.  Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.

Authors:  Ning Sun; Huimin Zhao
Journal:  Biotechnol Bioeng       Date:  2013-08-26       Impact factor: 4.530

7.  Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.

Authors:  Jian Xu; Daniel E Bauer; Marc A Kerenyi; Thuy D Vo; Serena Hou; Yu-Jung Hsu; Huilan Yao; Jennifer J Trowbridge; Gail Mandel; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

8.  HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers.

Authors:  Ralph Stadhouders; Suleyman Aktuna; Supat Thongjuea; Ali Aghajanirefah; Farzin Pourfarzad; Wilfred van Ijcken; Boris Lenhard; Helen Rooks; Steve Best; Stephan Menzel; Frank Grosveld; Swee Lay Thein; Eric Soler
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

9.  Altered translation of GATA1 in Diamond-Blackfan anemia.

Authors:  Leif S Ludwig; Hanna T Gazda; Jennifer C Eng; Stephen W Eichhorn; Prathapan Thiru; Roxanne Ghazvinian; Tracy I George; Jason R Gotlib; Alan H Beggs; Colin A Sieff; Harvey F Lodish; Eric S Lander; Vijay G Sankaran
Journal:  Nat Med       Date:  2014-06-22       Impact factor: 53.440

10.  Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.

Authors:  Fei Xie; Lin Ye; Judy C Chang; Ashley I Beyer; Jiaming Wang; Marcus O Muench; Yuet Wai Kan
Journal:  Genome Res       Date:  2014-08-05       Impact factor: 9.043

View more
  91 in total

1.  Pharmacologic control of chromatin looping.

Authors:  Marjorie Brand
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

Review 2.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

3.  Reexamination of hemoglobin adjustments to define anemia: altitude and smoking.

Authors:  Andrea J Sharma; O Yaw Addo; Zuguo Mei; Parminder S Suchdev
Journal:  Ann N Y Acad Sci       Date:  2019-06-23       Impact factor: 5.691

4.  BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.

Authors:  Anindita Basak; Miroslava Hancarova; Jacob C Ulirsch; Tugce B Balci; Marie Trkova; Michal Pelisek; Marketa Vlckova; Katerina Muzikova; Jaroslav Cermak; Jan Trka; David A Dyment; Stuart H Orkin; Mark J Daly; Zdenek Sedlacek; Vijay G Sankaran
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

5.  Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.

Authors:  Gaurang Trivedi; Daichi Inoue; Cynthia Chen; Lillian Bitner; Young Rock Chung; Justin Taylor; Mithat Gönen; Jürgen Wess; Omar Abdel-Wahab; Lingbo Zhang
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

Review 6.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

7.  Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.

Authors:  Quan Li; Eric R Henry; James Hofrichter; Jeffrey F Smith; Troy Cellmer; Emily B Dunkelberger; Belhu B Metaferia; Stacy Jones-Straehle; Sarah Boutom; Garrott W Christoph; Terri H Wakefield; Mary E Link; Dwayne Staton; Erica R Vass; Jeffery L Miller; Matthew M Hsieh; John F Tisdale; William A Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

8.  Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis.

Authors:  Rajiv K Khajuria; Mathias Munschauer; Jacob C Ulirsch; Claudia Fiorini; Leif S Ludwig; Sean K McFarland; Nour J Abdulhay; Harrison Specht; Hasmik Keshishian; D R Mani; Marko Jovanovic; Steven R Ellis; Charles P Fulco; Jesse M Engreitz; Sabina Schütz; John Lian; Karen W Gripp; Olga K Weinberg; Geraldine S Pinkus; Lee Gehrke; Aviv Regev; Eric S Lander; Hanna T Gazda; Winston Y Lee; Vikram G Panse; Steven A Carr; Vijay G Sankaran
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

9.  Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice.

Authors:  Claudia Fiorini; Nour J Abdulhay; Sean K McFarland; Mathias Munschauer; Jacob C Ulirsch; Roberto Chiarle; Vijay G Sankaran
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

Review 10.  Society for Pediatric Research 2015 Young Investigator Award: genetics of human hematopoiesis-what patients can teach us about blood cell production.

Authors:  Aoi Wakabayashi; Vijay G Sankaran
Journal:  Pediatr Res       Date:  2015-11-17       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.